Drugs that Affect the Renin-Angiotensin-Aldosterone System (RAAS)
The Renin-Angiotensin-Aldosterone System (RAAS) is a hormone system that plays a crucial role in regulating blood pressure, fluid and electrolyte balance, and systemic vascular resistance. Dysregulation of this system can lead to conditions like hypertension, heart failure, and chronic kidney disease.
Classification
- 1. Renin Inhibitors:
- Aliskiren
- 2. Angiotensin-Converting Enzyme (ACE) Inhibitors:
- Enalapril
- Ramipril
- Lisinopril
- Captopril
- 3. Angiotensin II Receptor Blockers (ARBs):
- Losartan
- Valsartan
- Candesartan
- 4. Aldosterone Antagonists:
- Spironolactone
Pharmacodynamics
- 1. Direct Renin Inhibitors:
- Aliskiren directly inhibits renin, reducing the conversion of angiotensinogen to angiotensin I, thereby decreasing the production of angiotensin II. This leads to reduced vasoconstriction and aldosterone secretion.
- 2. ACE Inhibitors:
- ACE inhibitors work by inhibiting the angiotensin-converting enzyme (ACE), which prevents the conversion of angiotensin I to angiotensin II. The reduction in angiotensin II leads to decreased vasoconstriction, aldosterone secretion, and blood pressure.
- 3. Angiotensin II Receptor Blockers (ARBs):
- ARBs block the binding of angiotensin II to its receptors, thus preventing its vasoconstrictive effects and the release of aldosterone.
- 4. Aldosterone Antagonists:
- Spironolactone and other aldosterone antagonists block the action of aldosterone at its receptors in the kidneys, leading to decreased sodium and water retention and promoting potassium retention, which helps in managing conditions like heart failure and hypertension.